Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 Q2- Text added to 2021 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abemaciclib, American, anticancer, arm, ASCO, biomarker, cleaning, closure, cohort, confirmed, correlated, cutoff, deposit, disinfection, distinguished, enhanced, entry, escalation, feet, final, fire, Florida, foot, foreseeable, free, Gilead, hematocrit, inflation, landlord, learned, lesion, liver, lockdown, median, mg, Miami, month, nationwide, nuclei, optionee, pathway, paused, PDUFA, percent, preliminary, presence, progression, region, relevant, resignation, restart, resumed, robust, sacituzumab, Similarly, Society, square, stable, staffing, staining, tenant, threshold, tissue, toxicity, tracing, trademark, Trodelvy, vaccination, week
Removed:
begin, issue, size
Valuein 2021 Q2 filing- Value in 2021 Q3 filing
Original filings
Filing view